TISIDB

Summary
Symbol	NRBF2
Name	nuclear receptor binding factor 2
Aliases	DKFZp564C1664; FLJ30395; COPR1; COPR2; comodulator of PPAR and RXR 1; comodulator of PPAR and RXR 2; COPR; N ......
Chromosomal Location	10q22.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Nucleus Cytoplasm Cytoplasmic vesicle Cytoplasmic vesicle, autophagosome
Domain	PF08961 Nuclear receptor-binding factor 2 PF17169 MIT domain of nuclear receptor-binding factor 2
Function	May modulate transcriptional activation by target nuclear receptors. Can act as transcriptional activator (in vitro). ; FUNCTION: Involved in starvation-induced autophagy probably by its association with PI3K complex I (PI3KC3-C1). However, effects has been described variably. Involved in the induction of starvation-induced autophagy (PubMed:24785657). Stabilzes PI3KC3-C1 assembly and enhances ATG14-linked lipid kinase activity of PIK3C3 (By similarity). Proposed to negatively regulate basal and starvation-induced autophagy and to inhibit PIK3C3 activity by modulating interactions in PI3KC3-C1 (PubMed:25086043). May be involved in autophagosome biogenesis (PubMed:25086043). May play a role in neural progenitor cell survival during differentiation (By similarity).

> Gene Ontology [ TOP ]
Biological Process	GO:0006352 DNA-templated transcription, initiation GO:0006367 transcription initiation from RNA polymerase II promoter GO:0006914 autophagy GO:0010506 regulation of autophagy GO:0019216 regulation of lipid metabolic process GO:0034976 response to endoplasmic reticulum stress GO:0043550 regulation of lipid kinase activity
Molecular Function	-
Cellular Component	GO:0005776 autophagosome GO:0005942 phosphatidylinositol 3-kinase complex GO:0019898 extrinsic component of membrane GO:0035032 phosphatidylinositol 3-kinase complex, class III GO:0061695 transferase complex, transferring phosphorus-containing groups

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04140 Regulation of autophagy
Reactome	R-HSA-74160: Gene Expression R-HSA-212436: Generic Transcription Pathway R-HSA-383280: Nuclear Receptor transcription pathway

Summary
Symbol	NRBF2
Name	nuclear receptor binding factor 2
Aliases	DKFZp564C1664; FLJ30395; COPR1; COPR2; comodulator of PPAR and RXR 1; comodulator of PPAR and RXR 2; COPR; N ......
Chromosomal Location	10q22.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between NRBF2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	NRBF2
Name	nuclear receptor binding factor 2
Aliases	DKFZp564C1664; FLJ30395; COPR1; COPR2; comodulator of PPAR and RXR 1; comodulator of PPAR and RXR 2; COPR; N ......
Chromosomal Location	10q22.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of NRBF2 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	logFC: -2.70; FDR: 0.04630	Resistant to T cell-mediated killing
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	logFC: -2.41; FDR: 0.02150	Resistant to T cell-mediated killing
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	NRBF2
Name	nuclear receptor binding factor 2
Aliases	DKFZp564C1664; FLJ30395; COPR1; COPR2; comodulator of PPAR and RXR 1; comodulator of PPAR and RXR 2; COPR; N ......
Chromosomal Location	10q22.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of NRBF2 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.235	0.284
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.48	0.793
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.058	0.965
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.17	0.524
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.294	0.826
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.01	0.996
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.012	0.973
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.117	0.934
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.188	0.907
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.439	0.677
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.753	0.655
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.11	0.115

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of NRBF2 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	1

Summary
Symbol	NRBF2
Name	nuclear receptor binding factor 2
Aliases	DKFZp564C1664; FLJ30395; COPR1; COPR2; comodulator of PPAR and RXR 1; comodulator of PPAR and RXR 2; COPR; N ......
Chromosomal Location	10q22.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of NRBF2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	NRBF2
Name	nuclear receptor binding factor 2
Aliases	DKFZp564C1664; FLJ30395; COPR1; COPR2; comodulator of PPAR and RXR 1; comodulator of PPAR and RXR 2; COPR; N ......
Chromosomal Location	10q22.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of NRBF2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by NRBF2. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	NRBF2
Name	nuclear receptor binding factor 2
Aliases	DKFZp564C1664; FLJ30395; COPR1; COPR2; comodulator of PPAR and RXR 1; comodulator of PPAR and RXR 2; COPR; N ......
Chromosomal Location	10q22.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of NRBF2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	NRBF2
Name	nuclear receptor binding factor 2
Aliases	DKFZp564C1664; FLJ30395; COPR1; COPR2; comodulator of PPAR and RXR 1; comodulator of PPAR and RXR 2; COPR; N ......
Chromosomal Location	10q22.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of NRBF2 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	NRBF2
Name	nuclear receptor binding factor 2
Aliases	DKFZp564C1664; FLJ30395; COPR1; COPR2; comodulator of PPAR and RXR 1; comodulator of PPAR and RXR 2; COPR; N ......
Chromosomal Location	10q22.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between NRBF2 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	NRBF2
Name	nuclear receptor binding factor 2
Aliases	DKFZp564C1664; FLJ30395; COPR1; COPR2; comodulator of PPAR and RXR 1; comodulator of PPAR and RXR 2; COPR; N ......
Chromosomal Location	10q22.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting NRBF2 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse NRBF2